KLKue Peng Lim

Kue Peng Lim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kue Peng Lim has a total of 87 co-authors. Here are the top co-authors by number of shared publications:

  • Sok Ching Cheong

    Cancer Immunology and Immunotherapy Unit, Cancer Research Malaysia, Selangor, Malaysia

    5 shared publications
  • Natasha Zulaziz

    Cancer Immunology & Immunotherapy Research Unit, Cancer Research Malaysia, Subang Jaya, Malaysia

    4 shared publications
  • Bernard Kok Bang Lee

    Department of Mathematical Sciences, Faculty of Science and Technology, Universiti Kebangsaan Malaysia, Bangi, Malaysia

    3 shared publications
  • Chai Phei Gan

    Cancer Immunology & Immunotherapy Research Unit, Cancer Research Malaysia, Subang Jaya, Malaysia

    3 shared publications
  • Shin Hin Lau

    Cancer Immunology and Immunotherapy Unit, Cancer Research Malaysia, Subang Jaya, Malaysia

    3 shared publications
  • Sok Ching Cheong

    Cancer Research Malaysia, Subang Jaya, Selangor, Malaysia

    3 shared publications

Latest Publications

  • Cancer cell membrane-coated liposomal nanovaccine integrating HER2-derived multi-epitope peptides for prophylactic breast cancer immunization

    by Anushri Sambanthan, Qatada Adam, Fadhlullah Zuhair Js, Pei Yuen Ng, Khatijah Yusoff, Nadiah Abu, Mariusz Skwarczynski, Kue Peng Lim, Fazren Azmi

  • Open Access

    Cancer cell membrane-coated liposomal nanovaccine integrating HER2-derived multi-epitope peptides for prophylactic breast cancer immunization

    by Fazren Azmi, Anushri Sambanthan, Qatada Adam, Fadhlullah Js, Pei Yuen Ng, Khatijah Yusoff, Nadiah Abu, Mariusz Skwarczynski, Kue Peng Lim

    Peptide-based cancer vaccines offer high antigen specificity but are frequently limited by rapid degradation, inefficient delivery, and insufficient immune priming, particularly due to tumor antigen heterogeneity. To address these challenges, we developed a biomimetic liposomal nanovaccine that integrates defined HER2-derived peptide epitopes with native tumor antigens through cancer cell membrane (CCM) functionalization. A HER2-derived multi-epitope peptide comprising cytotoxic T-lymphocyte and B-cell epitopes, conjugated to keyhole limpet hemocyanin (KLH), was encapsulated within liposomes, followed by surface coating with CCM to reconstruct a tumor-mimetic nano–bio interface for enhanced immune recognition. The nanovaccine formulation was optimized for peptide encapsulation efficiency, membrane coating integrity, and particle size distribution. In vivo immunization studies in BALB/c mice demonstrated that CCM-coated liposomal nanovaccines elicited significantly enhanced HER2-specific humoral and cellular immune responses, including elevated IgG titers, increased splenocyte proliferation, and augmented IFN-γ secretion, without inducing reactogenicity or excessive inflammatory responses. Importantly, prophylactic efficacy was strongly influenced by the source of the CCM, with antigen-matched membranes producing superior tumor growth suppression and prolonged survival compared with mismatched membrane coatings in a HER2-positive breast cancer challenge model. Overall, this study demonstrates that rational integration of well-defined HER2 peptide epitopes with homologous CCM antigens within a single liposomal delivery system can substantially enhance immune priming and prophylactic efficacy. These findings highlight the critical role of membrane source selection in biomimetic nanovaccine design and provide a conceptual avenue toward personalized cancer vaccination, wherein CCM may be sourced from individual tumors to tailor antigenic presentation.

  • Open Access

    Dual-antigen Doggybone TM DNA vaccine induces potent anti-tumor immunity against immunosuppressive oral cancer

    by Grace Min Yi Tan, Chuan Wang, Maria Martina Meschis, Josephine F Buckingham, Kue Peng Lim, Sok Ching Cheong, Gareth J. Thomas, Sungwon Kim, Lisa Caproni, Helen Horton, et al.

    Anti-PD1 blockade benefits only a subset of patients with head and neck squamous cell carcinoma (HNSCC), highlighting the need for approaches that overcome tumor immune resistance. Here, using the doggybone DNA (dbDNA TM ) platform, we developed CaVac OPT, an optimized dual-antigen DNA vaccine targeting MAGED4B and FJX1, which are overexpressed in most HPV-negative HNSCC and multiple solid tumors. In the MOC-2 oral cancer model, CaVac OPT significantly reduced tumor growth and when combined with anti-PD1 therapy, further delayed progression and improved survival. Immune profiling showed increased infiltration of CD4 + and CD8 + T cells, expansion of stem-like Tcf1 + populations, without increase in regulatory T cells, a reduced M2/M1 macrophage ratio and activation of interferon gamma associated pathways with suppression of tumor-promoting signals. These findings demonstrate that CaVac OPT reprograms the tumor microenvironment, converting cold HNSCC into T cell-inflamed responsive tumors. CaVac OPT represents a promising strategy for achieving durable control of aggressive, immunotherapy-resistant head and neck cancer.

  • Open Access

    Cancer vaccine overcomes immune evasion of nasopharyngeal carcinoma by restoring MHC-I through transcriptional regulation of NLRC5

    by Chai Phei Gan, Sau Yee Kok, Bernard Kok Bang Lee, Natasha Zulaziz, Sok Ching Cheong, Natalia Savelyeva, Kue Peng Lim

    Nasopharyngeal carcinoma (NPC) is considered an immune-hot tumour. However, 30–80% of cases exhibit downregulation of antigen processing and presenta


  • Open Access

    Cancer vaccine overcomes immune evasion of nasopharyngeal carcinoma by restoring MHC-I through transcriptional regulation of NLRC5

    by Chai Phei Gan, Sau Yee Kok, Bernard Kok Bang Lee, Natasha Zulaziz, Sok Ching Cheong, Natalia Savelveya, Kue Peng Lim

    Background Nasopharyngeal carcinoma (NPC) is considered an immune-hot tumour. However, 30–80% of cases exhibit downregulation of antigen processing and presentation machinery (APM), enabling the evasion of host immunosurveillance. While cancer vaccines aim to trigger immune responses against tumour antigens, their efficacy in APM-deficient tumours remains uncertain. This study evaluates the efficacy of cancer vaccine targeting tumour-associated antigens in APM-downregulated NPC cells in vitro and further validates the modulation of APM pathways in vivo . Methods APM status was evaluated via differential gene expression analysis of 42 NPC tumours and 4 non-NPC tissues using a 17-gene APM signature. Genes downregulated in NPC and associated with reduced MHC-I expression were identified. MHC-I expression was further examined by immunohistochemistry in 35 tumours and 5 non-NPC tissues. The effect of cancer vaccine on APM gene expression was examined by co-culturing peptide-trained T cells with NPC cells. Next, T cell-mediated cytotoxicity was assessed in an APM-deficient model generated by siRNA-mediated knockdown of NLRC5 . Finally, cancer vaccine-induced modulation of APM genes was validated in a poorly immunogenic mouse tumour model. Results Among the 17-gene APM signature, NLRC5 was the most significantly downregulated gene in NPC and strongly correlated with reduced MHC-I expression. Immunohistochemistry confirmed MHC-I downregulation in 63% of tumours. Co-culture of NPC cells with peptide-trained T cells upregulated NLRC5, and key MHC-I assembly genes (TAP1 and B2M), enhancing MHC-I expression and antigen-specific cytotoxicity in NPC cells expressing the target antigen. Notably, the knockdown of NLRC5 was reversed upon co-culture with peptide-trained T cells, resulting in T cell-mediated cytotoxicity. In vivo , cancer vaccine treatment consistently induced APM gene expression, including NLRC5, supporting its potential in restoring antigen presentation in NPC. Conclusions This study demonstrates that peptide-trained T cells can upregulate NLRC5 and MHC-I expressions on tumour cells, thereby restoring antigen presentation and enhancing tumour immunogenicity. These findings underscore the therapeutic potential of cancer vaccines in treating APM-downregulated NPC.

  • Open Access

    Pembrolizumab (MK-3475) plus platinum and gemcitabine as first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma (PIPER): a phase 2, multicentre, single-arm protocol study in Malaysia

    by Sok Ching Cheong, Bawani Selvam, Gwo Fuang Ho, Ibtisam Muhamad Nor, Chih Kiang Tan, Yoke Fui Wong, Soo Hwang Teo, Kue Peng Lim, Annie Wai Yeeng Chai, Abqariyah Yahya, et al.

    Introduction: Treatment combination of pembrolizumab plus platinum and 5-fluorouracil (PF) has increased the survival of recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). The combination of platinum and gemcitabine (PG) has been shown to be superior to PF in the treatment of R/M nasopharyngeal carcinoma patients. Therefore, we hypothesise that the combination of pembrolizumab with PG would be comparable to pembrolizumab with PF as a first-line treatment in R/M HNSCC. Methods and analysis: This is an open-label, multicentre, single-arm, phase 2 study of pembrolizumab plus PG for first-line treatment in subjects with R/M HNSCC in Malaysia. The study is conducted using the Optional Simon optimal 2-stage design. At the initial stage, 26 subjects will be enrolled and if seven or more patients achieve an objective response rate (ORR), then 63 patients will be enrolled. Subjects will be given pembrolizumab 200 mg3 every 3 weeks up to 35 cycles in combination with chemotherapy for up to six cycles of platinum (either cisplatin at 35 mg/m2 intravenous on day 1 and day 8 or carboplatin at area under the curve 5 intravenous on day 1 of each 3-week cycle) and gemcitabine at 1250 mg/m2 intravenous on days 1 and 8 of a 3-week cycle. The primary end point is the ORR as per Response Evaluation Criteria in Solid Tumors 1.1. Secondary end points include the overall survival, progression free survival, response duration and safety. The exploratory objectives include relationships of microbiome profiles, prognostic and predictive biomarkers with the clinical responses. Ethics and dissemination: The study was approved by the ethics committee of the University Malaya Medical Centre (202213–10884). Findings will be disseminated through conference presentations and peer review publications. Trial registration number: ClinicalTrials.gov (www.clinicaltrial.gov); NCT05286619.


  • Open Access

    Peptide-Based Vaccine against Breast Cancer: Recent Advances and Prospects

    by Muhammad Luqman Nordin, Ahmad Khusairi Azemi, Abu Hassan Nordin, Walid Nabgan, Pei Yuen Ng, Khatijah Yusoff, Nadiah Abu, Kue Peng Lim, Zainul Amiruddin Zakaria, Noraznawati Ismail, et al.

    Breast cancer is considered the second-leading cancer after lung cancer and is the most prevalent cancer among women globally. Currently, cancer immunotherapy via vaccine has gained great attention due to specific and targeted immune cell activity that creates a potent immune response, thus providing long-lasting protection against the disease. Despite peptides being very susceptible to enzymatic degradation and poor immunogenicity, they can be easily customized with selected epitopes to induce a specific immune response and particulate with carriers to improve their delivery and thus overcome their weaknesses. With advances in nanotechnology, the peptide-based vaccine could incorporate other components, thereby modulating the immune system response against breast cancer. Considering that peptide-based vaccines seem to show remarkably promising outcomes against cancer, this review focuses on and provides a specific view of peptide-based vaccines used against breast cancer. Here, we discuss the benefits associated with a peptide-based vaccine, which can be a mainstay in the prevention and recurrence of breast cancer. Additionally, we also report the results of recent trials as well as plausible prospects for nanotechnology against breast cancer.


  • Open Access

    The origins, roles and therapies of cancer associated fibroblast in liver cancer

    by Natasha Zulaziz, San Jiun Chai, Kue Peng Lim

    Hepatocellular carcinoma (HCC) is the most common form of liver cancer. It is often preceded by chronic inflammation such as liver fibrosis and cirrhosis. Different cell types are believed to give rise to liver-specific cancer associated fibroblast (CAF), these include resident fibroblast, hepatic stellate cell, liver cancer cell, hepatic sinusoidal endothelial cell and mesenchymal stromal cell. The abundance of fibroblasts has contributed to the cancer progression, immune modulation and treatment resistance in HCC. In this review, we discussed the origins, subtypes and roles of cancer associated fibroblasts in HCC. Their specific roles in shaping the tumor microenvironment, facilitating cancer growth, and modulating different immune cell types to confer a permissive environment for cancer growth. CAF is now an attractive therapeutic target for cancer treatment, however specific therapeutic development in HCC is still lacking. Hence, we have included preclinical and clinical development of CAF-specific interventions for other cancer types in this review. However, most CAF-specific therapies have resulted in disappointing clinical outcomes, likely due to the difficulties in differentiating CAF from normal fibroblast. A thorough understanding of the characteristics and functionalities of CAF is warranted to further improve the therapeutic efficacy of anti-CAF therapies.


  • Open Access

    Transcriptional analysis highlights three distinct immune profiles of high-risk oral epithelial dysplasia

    by Chai Phei Gan, Bernard Kok Bang Lee, Shin Hin Lau, Thomas George Kallarakkal, Zuraiza Mohamad Zaini, Bryan Kit Weng Lye, Rosnah Binti Zain, Hans Prakash Sathasivam, Joe Poh Sheng Yeong, Natalia Savelyeva, et al.

    Oral potentially malignant disorders (OPMD) are precursors of oral squamous cell carcinoma (OSCC), and the presence of oral epithelial dysplasia (OED) in OPMD confers an increased risk of malignant transformation. Emerging evidence has indicated a role for the immune system in OPMD disease progression; however, the underlying immune mechanisms remain elusive. In this study, we used immune signatures established from cancer to delineate the immune profiles of moderate and severe OED, which are considered high-risk OPMD. We demonstrated that moderate and severe OEDs exhibit high lymphocyte infiltration and upregulation of genes involved in both immune surveillance (major histocompatibility complex-I, T cells, B cells and cytolytic activity) and immune suppression (immune checkpoints, T regulatory cells, and tumor-associated macrophages). Notably, we identified three distinct subtypes of moderate and severe OED: immune cytotoxic, non-cytotoxic and non-immune reactive. Active immune surveillance is present in the immune cytotoxic subtype, whereas the non-cytotoxic subtype lacks CD8 immune cytotoxic response. The non-immune reactive subtype showed upregulation of genes involved in the stromal microenvironment and cell cycle. The lack of T cell infiltration and activation in the non-immune reactive subtype is due to the dysregulation of CTNNB1, PTEN and JAK2. This work suggests that moderate and severe OED that harbor the non-cytotoxic or non-immune reactive subtype are likely to progress to cancer. Overall, we showed that distinct immune responses are present in high-risk OPMD, and revealed targetable pathways that could lead to potential new approaches for non-surgical management of OED.


  • Open Access

    DNA Vaccines Targeting Novel Cancer-Associated Antigens Frequently Expressed in Head and Neck Cancer Enhance the Efficacy of Checkpoint Inhibitor

    by Chuan Wang, Nur Syafinaz Zainal, San Jiun Chai, James Dickie, Chai Phei Gan, Natasha Zulaziz, Bryan Kit Weng Lye, Ruhcha V. Sutavani, Christian H. Ottensmeier, Emma V. King, et al.

    HPV-independent head and neck squamous cell carcinoma (HNSCC) is a common cancer globally. The overall response rate to anti-PD1 checkpoint inhibitors (CPIs) in HNSCC is ~16%. One major factor influencing the effectiveness of CPI is the level of tumor infiltrating T cells (TILs). Converting TILlow tumors to TILhigh tumors is thus critical to improve clinical outcome. Here we describe a novel DNA vaccines to facilitate the T-cell infiltration and control tumor growth. We evaluated the expression of target antigens and their respective immunogenicity in HNSCC patients. The efficacy of DNA vaccines targeting two novel antigens were evaluated with or without CPI using a syngeneic model. Most HNSCC patients (43/44) co-expressed MAGED4B and FJX1 and their respective tetramer-specific T cells were in the range of 0.06-0.12%. In a preclinical model, antigen-specific T cells were induced by DNA vaccines and increased T cell infiltration into the tumor, but not MDSC or regulatory T cells. The vaccines inhibited tumor growth and improved the outcome alone and upon combination with anti-PD1 and resulted in tumor clearance in approximately 75% of mice. Pre-existence of MAGED4B and FJX1-reactive T cells in HNSCC patients suggests that these widely expressed antigens are highly immunogenic and could be further expanded by vaccination. The DNA vaccines targeting these antigens induced robust T cell responses and with the anti-PD1 antibody conferring excellent tumor control. This opens up an opportunity for combination immunotherapy that might benefit a wider population of HNSCC patients in an antigen-specific manner.